The FDA grants Fast Track designation to nipocalimab for systemic lupus erythematosus following positive results from the phase 2b JASMINE trial.

Phase 3 trial data show that obinutuzumab significantly reduces disease activity in very active extrarenal lupus.

Johnson & Johnson's nipocalimab has been granted U.S. Food and Drug Administration Fast Track designation as a potential ...

Lupus is more common in Black people, and symptoms can be different too. Here's what to look out for and how to treat it.

New analysis of Gazyva® shows the drug significantly reduces disease activity in adults with systemic lupus erythematosus.

A machine learning-driven framework accurately predicts MPA exposure and supports individualized dosing in childhood-onset LN.

An already-approved IV drug significantly reduces the symptoms of lupus, a new clinical trial showed. More than three-quarters of lupus patients taking obinutuzumab (Gazvya) had a significant ...

Shontia Matlock was 19 and pregnant when she was diagnosed with lupus, a chronic autoimmune disease that can cause fatigue, joint pain, and skin changes. It wasn’t a total shock. “Everybody in my ...

This explainer details common lupus warning signs and why early recognition matters for clinical assessment. It outlines lupus symptoms such as photosensitivity associated with rashes, low-grade fever ...

What Is Adquey, and Why Does It Matter? Adquey (difamilast 1%) is a prescription ointment the FDA has approved for adults and for children 2 and older who have mild to moderate atopic dermatitis (AD), ...

Lupus is a complex autoimmune disease that can affect any part of the body, and its symptoms often appear gradually, come and go, or look like those of other conditions. If you think you might have ...